JAKKS Pacific, Inc. (JAKK)

Marinus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	38.2	69.94	72.35	85.3	44.52	87.95
Cash & Short-Term Investments	38.2	69.94	72.35	85.3	44.52	87.95
Cash Growth	115.79%	-3.34%	-15.18%	91.59%	-49.38%	42.75%
Accounts Receivable	124.49	131.63	123.8	102.77	147.39	102.25
Other Receivables	10.25	8.8	2.67	2.22	1.53	0.93
Receivables	134.74	140.43	126.47	104.99	148.92	103.18
Inventory	71.81	52.78	52.65	80.62	83.95	38.64
Prepaid Expenses	5.78	2.31	1.72	0.99	4.15	2.49
Restricted Cash	4.86	0.2	0.2	0.19	0.81	4.74
Other Current Assets	6.55	3.04	1.98	3.12	5.2	13.82
Total Current Assets	261.93	268.69	255.37	275.21	287.56	250.83
Property, Plant & Equipment	69.7	68.9	38.19	34.78	30.1	37.9
Goodwill	34.95	35.11	35.08	35.08	35.08	35.08
Other Intangible Assets	-	-	-	-	1.32	2.33
Long-Term Deferred Tax Assets	70.4	70.39	68.14	57.8	-	-
Other Long-Term Assets	1.73	1.78	2.16	2.47	2.99	3.22
Total Assets	438.72	444.87	398.95	405.34	357.05	329.37
Accounts Payable	65.42	56.02	54.44	43.51	66.13	40.5
Accrued Expenses	45.89	46.08	43.25	35.56	38.96	35.77
Short-Term Debt	-	-	-	25.53	2.1	5.95
Current Portion of Leases	12.41	8.09	7.38	10.75	10.48	9.93
Current Income Taxes Payable	-	1.04	3.79	8.17	1	0.48
Current Unearned Revenue	-	0.25	0.7	0.92	2.51	0.94
Other Current Liabilities	29.12	37.95	39.69	53.4	51.89	44.71
Total Current Liabilities	152.83	149.42	149.23	177.82	173.07	138.27
Long-Term Debt	-	-	-	41.62	93.42	150.41
Long-Term Leases	43.88	48.43	16.67	9.86	8.04	16.88
Long-Term Deferred Tax Liabilities	-	-	-	-	0.05	0.12
Other Long-Term Liabilities	5.27	6.18	6.99	2.93	0.22	9.01
Total Liabilities	201.98	204.04	172.89	232.24	274.79	314.69
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	299.11	297.2	278.64	275.19	272.94	221.59
Retained Earnings	-49.97	-39.69	-73.61	-112.02	-203.43	-197.42
Comprehensive Income & Other	-12.92	-17.18	-15.63	-17.48	-12.95	-12.45
Total Common Equity	236.24	240.33	189.41	145.7	56.57	11.73
Minority Interest	0.5	0.5	0.71	1	1.33	1.21
Shareholders' Equity	236.74	240.83	226.06	173.11	82.26	14.68
Total Liabilities & Equity	438.72	444.87	398.95	405.34	357.05	329.37
Total Debt	56.29	56.52	24.05	87.76	114.04	183.17
Net Cash (Debt)	-18.09	13.41	48.3	-2.46	-69.51	-95.22
Net Cash Growth	-	-72.23%	-	-	-	-
Net Cash Per Share	-1.57	1.19	4.56	-0.24	-9.27	-26.20
Filing Date Shares Outstanding	11.15	11.15	10.8	9.87	9.57	5.57
Total Common Shares Outstanding	11.15	11.03	10.1	9.74	9.52	5.19
Working Capital	109.1	119.27	106.14	97.39	114.49	112.56
Book Value Per Share	21.19	21.80	18.76	14.96	5.94	2.26
Tangible Book Value	201.29	205.22	154.33	110.61	20.17	-25.69
Tangible Book Value Per Share	18.06	18.61	15.29	11.35	2.12	-4.95
Machinery	139.47	135.67	129.25	123.78	115.07	107.16
Leasehold Improvements	7.2	6.96	6.71	6.66	6.88	6.88

Updated Jul 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q